A. Milton

发表

Caregiver burden and emotional wellbeing in informal caregivers to ICU survivors - a prospective cohort study.

M. Bottai, A. Milton, A. Schandl, 2021, Acta anaesthesiologica Scandinavica.

Caregiver burden and emotional wellbeing in informal caregivers to ICU survivorsA prospective cohort study

M. Bottai, A. Milton, A. Schandl, 2021 .

Development of an ICU discharge instrument predicting psychological morbidity: a multinational study

M. Bottai, A. Milton, A. Schandl, 2018, Intensive Care Medicine.

Early psychological screening of intensive care unit survivors: a prospective cohort study

M. Bottai, A. Milton, A. Schandl, 2017, Critical Care.

Caregiver burden and emotional wellbeing in informal caregivers to ICU survivors—A prospective cohort study

M. Bottai, A. Milton, A. Schandl, 2020, Acta anaesthesiologica Scandinavica.

Single Deranged Physiologic Parameters Are Associated With Mortality in a Low-Income Country

A. Milton, J. Eriksen, T. Baker, 2015, Critical care medicine.

ICU discharge screening for prediction of new‐onset physical disability—A multinational cohort study

M. Bottai, A. Milton, A. Schandl, 2020, Acta anaesthesiologica Scandinavica.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, F. Ravandi, E. Jabbour, 2021, Blood.

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.